Compare Medpace Holdings Inc (MEDP) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Atlassian Corporation PLC — how do they compare? Medpace Holdings Inc trades at $616.5 (market cap $16.82B), while Atlassian Corporation PLC trades at $204.9 (market cap $51.53B). The key difference: Atlassian Corporation PLC is far larger — about 3.1× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 2,904,511). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Atlassian Corporation PLC for 64 Days on average.
| MEDP | TEAM | |
|---|---|---|
Market Cap | $16.82B | $51.53B |
Volume | 223,093 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $630.19 | $203.57 |
52-Week Low | $393.42 | $57.15 |
Typical Hold Time | 14 Days | 64 Days |
Enterprise Value | $16.44B | $51.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Atlassian (TEAM) trades at $195.67, up 0.87% with bullish technical signals and strong analyst support. The stock shows improving fundamentals with revenue growth from $2.8B in 2022 to $5.22B in 2025, though net margins remain negative. Recent earnings beats and AI-driven cloud adoption provide momentum, with the current price near resistance at $196.
Outlook remains positive given robust cloud growth and AI integration, but high valuations and persistent losses pose risks. Wall Street consensus is strongly bullish with 30 buy ratings and a $191.16 target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in the enterprise software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
